Zepbound is the newest GLP-1 medication on the block. While all of these medications share a similar mechanism of action, ...

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... reductions were likely driven by two main mechanisms of action -- the first being a ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

These are likely mechanisms by which GLP-1 may impact neuropsychiatric conditions.” — Ziyad Al-Aly, MD “I think there is clearly (an) added benefit for several conditions. For example ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...

An observational study of 175 health outcomes using Veterans Affairs (VA) data for nearly 2 million individuals uncovered new insights about possible risks and benefits of GLP-1 receptor agonists.